Mashup Score: 19 PHASE 2 STUDY OF ANBAL‐CEL, NOVEL ANTI‐CD19 CAR‐T THERAPY WITH DUAL SILENCING OF PD‐1 AND TIGIT IN RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA ‐ INTERIM ANALYSIS RESULT - 3 month(s) ago Click on the article title to read more. Source: onlinelibrary.wiley.com Categories: General Medicine News, Hem/Oncs Tweet Tweets with this article drjgauthier Exciting to hear the Korean experience with CAR T-cell therapy from Samsung Medical Center in Seoul from Dr. Seok Jin Kim! Looking forward to see updated results with anbal-cel https://t.co/jALYCVQC1K #ICBMT24 @ICBMT_Korea https://t.co/9NuPZRtRbI
Exciting to hear the Korean experience with CAR T-cell therapy from Samsung Medical Center in Seoul from Dr. Seok Jin Kim! Looking forward to see updated results with anbal-cel https://t.co/jALYCVQC1K #ICBMT24 @ICBMT_Korea https://t.co/9NuPZRtRbI